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Abstract 
Background: Many cardioprotective pharmacological agents failed to exert their protective effects in diabetic hearts 
subjected to myocardial ischemia/reperfusion (MI/R). Identify the molecular basis linking diabetes with MI/R injury 
is scientifically important and may provide effective therapeutic approaches. Dynamin-related protein 1 (Drp1)-
mediated mitochondrial fission plays an important role in MI/R injury under non-diabetic conditions. Importantly, 
recent studies indicated that Drp1-mediated mitochondrial fission is enhanced in the myocardium of diabetic mice. 
The above evidences suggested that Drp1 may be one critical molecule linking diabetes with MI/R injury. We hypoth-
esized that inhibition of Drp1 may be effective to reduce MI/R injury in diabetic hearts.
Methods: High-fat diet and streptozotocin-induced diabetic mice were subjected to MI/R or sham operation. 
Mdivi-1 (1.2 mg/kg), a small molecule inhibitor of Drp1 or vehicle was administrated 15 min before the onset of rep-
erfusion. Outcome measures included mitochondrial morphology, mitochondrial function, myocardial injury, cardiac 
function and oxidative stress.
Results: Mitochondrial fission was significantly increased following MI/R as evidenced by enhanced translocation 
of Drp1 to mitochondria and decreased mitochondrial size. Delivery of Mdivi-1 into diabetic mice markedly inhib-
ited Drp1 translocation to the mitochondria and reduced mitochondrial fission following MI/R. Inhibition of Drp1 in 
diabetic hearts improved mitochondrial function and cardiac function following MI/R. Moreover, inhibition of Drp1 
reduced myocardial infarct size and serum cardiac troponin I and lactate dehydrogenase activities. These cardio-
protective effects were associated with decreased cardiomyocyte apoptosis and malondialdehyde production and 
increased activities of antioxidant enzyme manganese superoxide dismutase.
Conclusions: Pharmacological inhibition of Drp1 prevents mitochondrial fission and reduces MI/R injury in diabetic 
mice. The findings suggest Drp1 may be a potential novel therapeutic target for diabetic cardiac complications.
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Background
It has been widely recognized that cardiovascular disease 
is the primary cause of death among diabetic subjects. 
Patients with diabetes face an increased risk of morbid-
ity from ischemic heart disease than non-diabetic popu-
lation, with exacerbated myocardial injury and cardiac 
dysfunction following ischemia/reperfusion (I/R) [1–3]. 
Moreover, ischemic precondition and many cardiopro-
tective pharmacological agents failed to exert their pro-
tective effects in diabetic ischemic hearts [4–6], which 
means many interventions that are effective in reducing 
myocardial ischemia/reperfusion (MI/R) injury are inef-
fective under diabetic condition. Therefore, identify the 
molecular basis linking diabetes with MI/R injury is sci-
entifically important and may provide effective therapeu-
tic approaches. As mitochondria have been considered as 
vital cell organelles in cardiomyocytes due to their pivotal 
role in ATP production required for myocardial contrac-
tion and survival, targeting mitochondrial pathological 
alterations may be one promising strategy against dia-
betic ischemic injury [7–9].
Recent studies indicate that mitochondria are dynamic 
organelles that undergo fission and fusion events, which 
serve to distribute mitochondria to daughter cells, to 
remove damaged mitochondria, and to help modulate 
cellular response to stress [10, 11]. Increased mitochon-
drial fission in the I/R heart has been demonstrated to 
contribute to reactive oxygen species (ROS) production 
and infarct generation, while inhibiting mitochondrial 
fission reduces myocardial injury and improves cardiac 
function following I/R [12, 13]. Dynamin-related protein 
1 (Drp1) is a cytosolic protein that is recruited over the 
mitochondrial surface to initiate fission through inter-
action with binding partners as fission protein 1 (Fis1) 
[14]. Drp1 is translocated to mitochondria in models of 
myocardial I/R, resulting in mitochondrial fission and 
dysfunction. Inhibition of Drp1 has been demonstrated 
to reduce mitochondrial fission and infarct size during 
I/R injury in non-diabetic animals [13, 15]. These studies 
suggest that Drp1-mediated mitochondrial fission plays 
an important role in myocardial ischemia/reperfusion 
(MI/R) injury under non-diabetic conditions.
Diabetes has a direct effect on mitochondrial dynam-
ics. Mitochondria become shorter and smaller under 
acute hyperglycemic conditions in a rapid response, 
which is also mediated by the fission protein Drp1 [16]. 
Increased mitochondrial fission associated with activated 
Drp1 is observed in coronary endothelial cells or cardiac 
myocytes from murine diabetic models [17, 18]. These 
studies indicate that Drp1-mediated mitochondrial fis-
sion is enhanced in diabetic hearts. The above evidences 
suggested that Drp1 may be one critical molecule linking 
diabetes with MI/R injury. Then, we hypothesized that 
inhibiting Drp1-mediated mitochondrial fission may 
reduce MI/R injury and improve cardiac function under 
diabetic conditions. The aims of this study were (1) to 
investigate whether an inhibitor of Drp1 was effective in 
reducing MI/R injury in diabetic animals, and if so, (2) 
further explore the underlying mechanisms.
Methods
Induction of type 2 diabetic mice
All animal experiments were performed in compli-
ance with the National Institutes of Health Guidelines 
on Animal Research. All experimental procedures were 
approved by the Fourth Military Medical University 
Ethics Committee. The high-fat diet (HFD) and strepto-
zotocin (STZ)-induced diabetic mouse model was devel-
oped according to previous studies from our lab and 
others [19, 20]. Male C57BL/6  J mice (8–10  weeks old) 
were fed with HFD (D12492, Research Diets) contain-
ing 60% fat (kcal%), 20% protein, and 20% carbohydrate 
for 4 weeks and then injected with a single low dose STZ 
(90 mg/kg, Sigma, St. Louis, MO, USA) intraperitoneally. 
One week after STZ injection, mice were considered to 
have developed diabetes and used for the study only if 
their 12-h fasting blood glucose levels were higher than 
11.1 mmol/L. The successful rate of diabetic model was 
91.4% (64 of 70 total mice). Fasting blood samples were 
collected to analyze serum TG (triacylglycerol) and insu-
lin levels. The level of serum TG was analyzed using an 
automatic biochemical analyzer (Advia 2400, Siemens, 
Germany). Serum insulin level was determined by using 
an enzyme linked immunosorbent assay.
Myocardial ischemia–reperfusion model
Mice were anesthetized by intraperitoneal injection of 
1% pentobarbital sodium. Myocardial ischemia was per-
formed by exteriorizing the heart followed by a slipknot 
at the distal 1/3 of the left anterior-descending (LAD) 
coronary artery origin with a 6-0 silk suture. The slip-
knot was released after occlusion for 30  min, and the 
myocardium was reperfused for 3  h (for determination 
of mitochondrial morphology and apoptosis) and 24  h 
(for measurement of infarct size and cardiac function) 
as illustrated in Fig. 1. The mice were placed in a sterile 
environment and received penicillin treatment (5 unit/
mice) to prevent infection at 3  h post-reperfusion. In 
sham-operated mice, the silk suture placed underneath 
the LAD artery was not ligated.
Diabetic mice were randomly assigned to receive either 
mdivi-1 (1.2 mg/kg), a small molecule inhibitor of Drp1 
or vehicle (dimethyl sulfoxide) 15 min before the onset of 
myocardial reperfusion by intraperitoneal injection. The 
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dose and route of mdivi-1 administration were chosen 
based on previous studies [15, 21, 22] and validated in 
our preliminary experiments.
Subcellular fractionation and western blotting analysis
Whole-cell lysates and mitochondrial fractions were 
obtained from mice hearts in different groups. Whole cell 
lysates were prepared as previously described [12]. Mito-
chondrial fractions were prepared by using the Mito-
chondria Isolation Kit (Beyotime Biotechnology, Jiangsu, 
China). Western blot analysis was performed as previ-
ously described [23]. The following primary antibodies 
were used: anti-Drp1 (Abcam), anti-VDAC1 (Abcam), 
and anti-GAPDH (Wuhan Boster Biological Technology).
Transmission electron microscopy
Ventricular samples were obtained from the proximal 
territory to artery occlusion site after 3  h of reperfu-
sion. Samples were fixed in 2.5% glutaraldehyde in 0.1 M 
sodium cacodylate buffer (pH 7.2) overnight at 4 °C and 
processed as described before [24]. Images were collected 
using a JEM-1230 transmission electron microscope 
(JEOL Ltd., Tokyo, Japan) at 300 kV with a charge-cou-
pled device (CCD) camera. Mitochondrial morphology 
was analyzed by using Image-Pro Plus software. For each 
heart, a minimum of 600 mitochondria was subjected to 
morphometric analysis. The percentage of mitochondria 
that fell into three size categories (smaller than 0.6 μm2, 
within 0.6–1.0 μm2, larger than 1.0 μm2) was analyzed in 
a given field according to previous studies [21, 25].
Determination of mitochondrial function
Mitochondrial electron transport chain complex (I–IV) 
activities were measured by using specific commercial 
kits (Shanghai GENMED Technology Co., LTD, China) 
according to the standard protocols. Intracellular ATP 
content was determined using ATP bioluminescent assay 
kits (Biovision) according to manufacturer’s protocols.
Assessment of cardiac function and myocardial infarct size
Cardiac function was measured by invasive hemody-
namic evaluation methods at 3  h post-reperfusion as 
previously described [26]. After 24  h of reperfusion, 
echocardiography was conducted with a VEVO 2100 
platform (Visual Sonics, Toronto, Canada). M-mode 
images were used to obtain left ventricular end-systolic 
volume (LVESV) and left ventricular end-diastolic vol-
ume (LVEDV) measurements and to calculate the per-
cent ejection fraction (%EF). After echocardiographic 
examination, myocardial infarct size (IS) was assessed by 
Evans blue/triphenyl tetrazolium chloride (TTC) double 
staining and calculated as a percent of infarcted area over 
total area-at-risk (% INF/AAR) as described before [27, 
28].
Determination of serum cardiac troponin I (cTnI) 
and lactate dehydrogenase
Blood samples were collected from the carotid artery 
after 3 h of reperfusion period. Serum cardiac troponin 
I (cTnI) and lactate dehydrogenase (LDH) levels were 
measured by using specific commercial kits (Nanjing 
jiancheng Reagents, China). The activities of these two 
enzymes were presented as nanogram per milliliter (ng/
ml) and units per liter (U/L) respectively.
Quantification of cardiomyocyte apoptosis
After 3 h of reperfusion, terminal deoxynucleotidyl nick-
end labeling (TUNEL) assay was used to detect cardio-
myocyte apoptosis. TUNEL staining was performed as 
described previously using in  situ cell death detection 
kits (Roche) [19]. The apoptosis index was expressed as 



















C57 mice 4 wks 1 wk
Fig. 1 Schematic representation of experimental protocol. Male C57 mice were fed with HFD for 4 weeks and then injected with streptozotocin 
(STZ) at the dose of 90 mg/kg intraperitoneally. One week after STZ injection, mice were considered to have developed diabetes only if their 12-h 
fasting blood glucose levels were higher than 11.1 mmol/L. The diabetic mice were subjected to 30 min ischemia followed by 3 h reperfusion (for 
determination of mitochondrial dynamics, mitochondrial function, myocardial apoptosis and ROS) or 24 h reperfusion (for determination of infarct 
size and cardiac function). Mdivi-1 (1.2 mg/kg) or vehicle (dimethyl sulfoxide) was administrated intraperitoneally 15 min before the onset of myo-
cardial reperfusion
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the total number of nucleated cells (4′,6-diamino-2-phe-
nylindole staining) ×100%. Myocardial caspase-3 activity 
was measured to detect cardiomyocyte apoptosis with 
the use of caspase colorimetric assay kits (Chemicon, 
Temecula, CA, USA) as we described before [29].
Quantification of malondialdehyde (MDA) and manganese 
superoxide dismutase activity (MnSOD)
The MDA levels in myocardial homogenates were deter-
mined as described before [30]. MnSOD activities were 
measured spectrophotometrically by using commercial 
kits (Beyotime, Jiangsu, China) according to manufac-
turer’s protocols.
Statistical analysis
All the data are presented as mean ±  standard error of 
the mean (SEM). The differences of all measured param-
eters were assessed by One-way ANOVA followed by 
Bonferroni post hoc test with the use of GraphPad Prism 




As shown in Table  1, compared with the non-diabetic 
mice, diabetic animals manifested significantly increased 
blood glucose and serum TG, indicating that type 2 dia-
betic model was created in this study. There was a small 
trend toward decreased serum insulin level and increased 
body weight that did not reach significance in diabetic 
mice compared to non-diabetic mice.
Mdivi‑1 inhibited Drp1 translocation to the mitochondria 
and reduced mitochondrial fission following I/R in diabetic 
hearts
As one major regulator of mitochondrial fission, Drp1 
typically resides in an inactive form in the cytosol and 
on activation translocates to the mitochondria. Drp1 will 
not dislocate from the mitochondria after fragmentation. 
The method that evaluates Drp1 activity by determining 
Drp1 protein level in the whole cell and mitochondria 
has been widely used in recent studies [31, 32]. Here, 
changes in the total Drp1 expression were not observed 
(Fig.  2a), while mitochondrial Drp1 expression in dia-
betic MI/R hearts was significantly increased compared 
to diabetic sham-operated hearts. By contrast, Mdivi-1 
reduced mitochondrial Drp1 expression following MI/R 
compared to MI/R receiving vehicle administration in 
diabetic mice (P < 0.01, Fig. 2b).
To determine whether changes in mitochondrial mor-
phology were associated with Drp1 activation follow-
ing MI/R, we isolated and prepared proximal areas to 
artery occlusion site for transmission electron micros-
copy. More mitochondria per μm2 were observed in I/R 
hearts compared to sham-operated hearts (P  <  0.05, 
Fig. 2c, d). Moreover, there was a significant increase in 
the percentage of mitochondria smaller than 0.6 μm2 in 
diabetic vehicle-treated MI/R hearts compared to dia-
betic sham-operated hearts (39.2 ±  2.1 vs. 18.1 ±  1.5% 
in Sham group, P < 0.01, Fig. 2d, e), suggesting enhanced 
mitochondrial fission. Diabetic MI/R mice treated with 
Mdivi-1 displayed reduced levels of mitochondrial fis-
sion compared to vehicle-treated mice as evidenced 
by decreased number of mitochondria per μm2 and 
decreased percentage of mitochondria smaller than 
0.6  μm2 (12.1  ±  1.6 vs. 39.2  ±  2.1% in MI/R group, 
P < 0.01, Fig. 2d, e). There was no significant difference in 
the percentage of mitochondria bigger than 1 μm2 among 
all the groups. The reason for this may be that elongated 
mitochondria are more resistant to MI/R injury than 
middle mitochondria. These findings suggested that 
Drp1-mediated mitochondrial fission was enhanced in 
diabetic MI/R hearts, and inhibition of Drp1 reduced 
mitochondrial fission in diabetic animals following MI/R.
Drp1 inhibition improved mitochondrial function 
in diabetic MI/R mice
It has been suggested that mitochondrial dynamics exerts 
a pivotal role in controlling mitochondrial function 
[33]. Here, mitochondrial complex I/II/III/IV activities 
and ATP content were significantly decreased in MI/R 
group treated with vehicle compared with sham group 
(P < 0.01, Fig. 3). Mdivi-1 increased mitochondrial com-
plex I/II/III/IV activities and ATP content in I/R myocar-
dium (P < 0.05 or P < 0.01, Fig. 3), indicating that Drp1 
inhibition improved mitochondrial function in diabetic 
MI/R hearts.
Drp1 inhibition improved cardiac function in diabetic MI/R 
mice
We next sought to explore if Mdivi-1 treatment 
would improve cardiac function following MI/R in 
diabetic mice. Echocardiography evaluated at 24  h 
Table 1 Characterization of animals
Values presented are mean ± SEM
DM high-fat diet-fed streptozotocin (HFD-STZ) diabetic group, TG triacylglycerol
N = 8
** p < 0.01 vs. Non-diabetic
Groups Non‑diabetic DM
Blood glucose (mmol/L) 4.6 ± 0.7 15.8 ± 2.3**
Serum insulin (mIU/L) 15.8 ± 2.1 13.2 ± 3.4
Serum TG (mmol/L) 0.46 ± 0.11 1.32 ± 0.18**
Body weight (g) 25.3 ± 2.5 28.8 ± 3.1
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post-reperfusion revealed that MI/R mice received 
Mdivi-1 treatment exhibited increased EF and decreased 
LVESV as compared with the MI/R group treated with 
vehicle (EF: 60.7  ±  4.1 vs. 44.6  ±  4.2% in MI/R group, 
P < 0.05, Fig. 4b; LVESV: 25.8 ± 2.7 vs. 36.3 ± 2.3 μL in 
MI/R group, P < 0.01, Fig. 4c). No significant differences 
in LVEDV were observed among all groups. Hemody-
namic measurements performed at 3 h post-reperfusion 
indicated that the  ±LV dp/dt max were increased in 
the MI/R +  Mdivi-1 group as compared with the MI/R 
Fig. 2 Mdivi-1 inhibited Drp1 translocation to the mitochondria and prevented mitochondrial fission following MI/R in diabetic mice. a Total Drp1 
expression. b Mitochondrial Drp1 expression. c Number of mitochondria per μm2 in each field of view. d Representative transmission electron 
microscopic images (major finding is c, e). e Percentage of mitochondria that sorted into three size categories based on area. MI/R group means 
diabetic mice subjected to MI/R and vehicle (dimethyl sulfoxide) administration. Values are mean ± SEM. N = 3–6 hearts for each group. *P < 0.05, 
**P < 0.01 vs. Sham. #P < 0.05, ##P < 0.01 vs. MI/R
Fig. 3 Mdivi-1 improved mitochondrial function in diabetic mice subjected to MI/R. a Complex I activity. b Complex II activity. c Complex III activity. 
d Complex IV activity. e ATP content. MI/R group means diabetic mice subjected to MI/R and vehicle (dimethyl sulfoxide) administration. Values are 
mean ± SEM. N = 8 hearts for each group. **P < 0.01 vs. Sham. #P < 0.05, ##P < 0.01 vs. MI/R
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group treated with vehicle (+LV dp/dt max: 2976 ± 175 
vs. 2274 ± 183 mmHg/s in MI/R group, P < 0.05, Fig. 4e; 
−LV dp/dt max: 2846 ± 169 vs. 2124 ± 163 mmHg/s in 
MI/R group, P  <  0.05, Fig.  4f ). These results suggested 
that Drp1 inhibition improved cardiac function in dia-
betic mice subjected to MI/R.
Drp1 inhibition attenuated MI/R injury in diabetic mice
To determine whether Drp1 inhibition might reduce 
MI/R injury, we measured serum cTnI and LDH levels 
and myocardial infarct size. Compared with sham group, 
serum cTnI and LDH levels were significantly increased 
in MI/R group treated with vehicle. Mdivi-1 administra-
tion reduced serum cTnI and LDH levels compared with 
that of MI/R group treated with vehicle (cTnI: 29.7 ± 5.1 
vs. 59.3  ±  8.1  ng/mL in MI/R group, P  <  0.01, Fig.  5a; 
LDH: 512 ± 47 vs. 784 ± 52 U/L in MI/R group, P < 0.01, 
Fig. 5b). Moreover, the MI/R mice received Mdivi-1 treat-
ment show a significant reduction in myocardial infarct 
size (28.7 ±  4.2 vs. 45.3 ±  4.7% in MI/R group, Fig. 5c, 
d, n =  8, P  <  0.01). The effects of Mdivi-1 on non-dia-
betic MI/R injury were also assessed in our preliminary 
study. It was found that inhibition of Drp1 significantly 
reduced infarct size and serum cardiac troponin I activity 
in MI/R mice without diabetes (Infarct size: 21.6 ± 2.7 vs. 
35.1 ±  3.8% in MI/R without diabetes; cTnI: 18.3 ±  2.4 
vs. 39.2 ±  3.6  ng/mL in MI/R without diabetes, n =  5, 
P < 0.05 or P < 0.01).
Another major form of cardiomyocyte death following 
MI/R is apoptosis, we then sought to determine whether 
Drp1 inhibition could reduce I/R-induced myocardial 
apoptosis under diabetic conditions. The MI/R mice 
treated with vehicle showed significantly increased apopto-
sis index (Fig. 6a) and caspase-3 activity (Fig. 6b) compared 
with that in sham mice. The MI/R mice received Mdivi-1 
administration exhibited suppressed myocardial apoptosis 
as indicated by decreased apoptosis index (10.3 ±  2.9 vs. 
30.6 ± 3.8% in MI/R group, P < 0.01, Fig. 6a) and caspase-3 
activity (2.5 ± 0.26 vs. 3.9 ± 0.21 in MI/R group, P < 0.01, 
Fig. 6b). These results indicated that Drp1 inhibition alle-
viated I/R-induced myocardial injury under diabetic condi-
tions in mice, which contributed to the improved recovery 
of cardiac function following MI/R as above.
Drp1 inhibition reduced oxidative stress in diabetic MI/R 
mice
Oxidative damage is a known consequence of MI/R and a 
likely contributor to cardiac dysfunction. Mitochondrial 
fission is also a contributor that promotes ROS produc-
tion [34]. We next sought to determine the effects of Drp1 
inhibition on oxidant production following MI/R under 
diabetic conditions. MDA is a major product of lipid per-
oxidation and MnSOD is an important antioxidant enzyme 
protecting mitochondria from oxidative damage, both 
of which are useful biomarkers for oxidant stress. There 
was increased MDA production and decreased MnSOD 
activity in MI/R group treated with vehicle in comparison 
with the sham group. In contrast, Mdivi-1 administration 
reduced MDA production and increased MnSOD activity 
in MI/R mice (MDA: 12.8 ±  1.9 vs. 21.5 ±  1.8  nmol/mg 
protein in MI/R group, P < 0.01, Fig. 7a; MnSOD: 7.1 ± 0.6 
vs. 4.3 ± 0.7 U/mg protein in MI/R group, P < 0.05, Fig. 7b). 
Fig. 4 Mdivi-1 improved cardiac function in diabetic mice subjected to MI/R. a Representative echocardiography images. b Left ventricular ejection 
fraction (LVEF). c Left ventricular end-systolic volume (LVESV). d Left ventricular end-diastolic volume (LVEDV). (E and F) ± LV dp/dt max, the instan-
taneous first derivation of left ventricle pressure. MI/R group means diabetic mice subjected to MI/R and vehicle (dimethyl sulfoxide) administration. 
Values are mean ± SEM. N = 8 animals for each group. **P < 0.01 vs. Sham. #P < 0.05, ##P < 0.01 vs. MI/R
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Fig. 5 Mdivi-1 reduced myocardial ischemia/reperfusion (MI/R) injury in diabetic mice. a Serum levels of cardiac troponin I (cTnI). b Serum levels of 
lactate dehydrogenase (LDH). c Representative images of myocardial infarct size stained by Evans blue and TTC. d Myocardial infarct size presented 
as percentage of infarct area (INF)/area at risk (AAR). MI/R group means diabetic mice subjected to MI/R and vehicle (dimethyl sulfoxide) administra-
tion. Values are mean ± SEM. N = 8 animals for each group. **P < 0.01 vs. Sham. ##P < 0.01 vs. MI/R
Fig. 6 Mdivi-1 suppressed myocardial apoptosis following myocardial ischemia/reperfusion (MI/R) in diabetic mice. a Top representative terminal 
deoxynucleotidyl nick-end labeling (TUNEL)-stained and 4’,6-diamino-2-phenylindole (DAPI)-stained photomicrographs. Original magnifica-
tion ×400. Bottom percentage of apoptotic cells (green fluorescence)/the total number of nucleated cells (blue fluorescence). b Myocardial cas-
pase-3 activity (fold over Sham). MI/R group means diabetic mice subjected to MI/R and vehicle (dimethyl sulfoxide) administration. Values are 
mean ± SEM. N = 8 hearts for each group. **P < 0.01 vs. Sham. ##P < 0.01 vs. MI/R
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These results suggested that Drp1 inhibition reduced I/R-
stimulated oxidative injury in diabetic animals.
Discussion
In this study, we demonstrate for the first time that Drp1-
mediated mitochondrial fission is increased following 
MI/R under diabetic conditions and that its inhibition with 
Mdivi-1 reduces MI/R injury and improves cardiac func-
tion. These findings, coupled with Mdivi-1’s preservation 
of mitochondrial function and reduction of oxidative stress, 
indicate an important pathological role of Drp1-mediated 
mitochondrial fission in diabetic MI/R injury. The findings 
suggest that Drp1 inhibition may represent a promising 
novel therapy for diabetic cardiac complications.
It has been demonstrated that mitochondrial dynam-
ics plays an important role in determining mitochondrial 
morphology and function [35]. However, this important 
issue has only begun to be addressed in cardiomyocytes 
during recent years, possibly due to the general percep-
tion that spatial constraint of the myofibril architec-
ture in adult ventricular cardiomyocytes may prevent 
mitochondrial dynamics. Interestingly, the proteins 
mediating mitochondrial dynamics are abundant in car-
diac tissue, suggesting their important roles in cardiac 
homeostasis [36, 37]. In this study, we showed that I/R 
induced significant myocardial injury and cardiac dys-
function in diabetic mice, which was accompanied by 
increased Drp1 activation and mitochondrial fission. 
Ong et al. have demonstrated that Mdivi-1 administrated 
15  min before myocardial ischemia protects the heart 
against myocardial ischemia/reperfusion (MI/R) injury 
under non-diabetic conditions [15]. It is important to 
note that MI/R injury is an acute and unpredictable 
event. Treatment remedy given at the time of reperfu-
sion reduces MI/R injury would be more meaningful to 
mimic clinical scenario. In the present study, Mdivi-1 
was administrated 15 min before the onset of reperfu-
sion, which may have better translational relevance to 
the clinical context. Moreover, Mdivi-1 sufficiently pre-
vented mitochondrial fission and reduced MI/R injury 
in diabetic mice as indicated by decreased serum cTnI/
LDH activities and infarct size. To the best of our knowl-
edge, this is the first study not only to find that inhibition 
of Drp1 reduced MI/R injury under diabetic conditions, 
but also to reveal that how MI/R injury was reduced 
(decreased myocardial necrosis and apoptosis and oxi-
dative stress) and how accompanying functional status 
was changed (improved mitochondrial function and 
cardiac function) in vivo. Our study extends Ong et al.’s 
findings and suggests that inhibition of Drp1 may have 
therapeutic effects for diabetic patients already diag-
nosed with ischemic heart disease. Targeting other pro-
teins involved in mitochondrial fission may also have 
cardioprotective effects. Inhibition of the interaction 
between Drp1 and mitochondrial fission protein 1 (Fis1) 
using P110 has been showed to reduce myocardial injury 
following MI/R [38] and may be a promising target for 
future studies on diabetic cardiac complications.
Mitochondrial fission is associated with most forms of 
cell death, while mitochondrial fusion protects against 
apoptosis [39]. Several studies of multiple apoptotic sys-
tems revealed that there were causal links between mito-
chondrial fission and the induction of cell death [10, 40]. 
During apoptosis, mitochondria become fragmented, 
which is dependent on the translocation of Drp1 from 
cytosol to mitochondria [41]. We have found increased 
Drp1 translocation to the mitochondria was accom-
panied by enhanced myocardial apoptosis in I/R myo-
cardium of diabetic animals. Moreover, inhibition of 
Drp1 significantly suppressed myocardial apoptosis as 
evidenced by decreased TUNEL-positive cells and cas-
pase-3 activity. Our data suggest that Drp1-mediated 
Fig. 7 Mdivi-1 suppressed oxidative stress following myocardial ischemia/reperfusion (MI/R) in diabetic mice. a The contents of myocardial malon-
dialdehyde (MDA). b The activity of mitochondrial manganese superoxide dismutase (MnSOD). MI/R group means diabetic mice subjected to MI/R 
and vehicle (dimethyl sulfoxide) administration. Values are mean ± SEM. N = 8 hearts for each group. **P < 0.01 vs. Sham. #P < 0.05, ##P < 0.01 vs. 
MI/R
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mitochondrial fission plays a pivotal role in myocardial 
apoptosis, a major form of cell death following I/R.
Numerous studies have demonstrated the frequent 
appearance of dysfunctional mitochondria in diabe-
tes and MI/R injury. Mitochondrial functional damage 
may lead to detrimental consequences on cardiac func-
tion and are considered to play an important role in 
the pathogenesis of cardiovascular disease [42, 43]. In 
accordance, our study identified that mitochondrial func-
tion was significantly impaired by I/R in diabetic hearts, 
as evidenced by decreased complex I/II/III/IV activities 
and ATP content. Mdivi-1 effectively rescued electron 
transport chain (ETC) activities and ATP content. These 
results indicated that inhibition of mitochondrial fission 
preserved mitochondrial function in diabetic I/R hearts, 
which may contribute to the improved recovery of car-
diac function as above.
In addition to ATP production, mitochondrial ETC 
has been recognized as a major source of ROS in cardio-
myocytes. It has been demonstrated that mitochondrial 
dysfunction caused increased ROS generation [44, 45]. 
In this study, we assessed MDA production and MnSOD 
activity as surrogate markers of oxidative stress. There 
was increased MDA production and decreased MnSOD 
activity following MI/R in diabetic mice. Mdivi-1 treat-
ment increased MnSOD activity and reduced MDA 
formation in diabetic I/R hearts, indicating that Drp1 
inhibition is effective to suppress I/R-induced oxidative 
stress in diabetic animals. The implied increased ROS fol-
lowing diabetic MI/R injury is generally known and simi-
lar to other studies [46–48], but its amelioration with a 
Drp1 inhibitor following MI/R under diabetic conditions 
is novel. Since we have provided evidence that Mdivi-1 
can rescue the activities of mitochondrial ETC, it is sug-
gested that inhibition of Drp1 may inhibit ROS produc-
tion directly at the source.
It needs to point out that this study has some limita-
tions. First, we investigated the effects of Drp1 inhibition 
in a high-fat diet and streptozotocin-induced diabetic 
model. The efficacy of Mdivi-1 in other diabetic mod-
els such as ob/ob mice remains to be studied. Second, 
Mdivi-1 was used as one pharmacological inhibitor of 
Drp1 in this study. Our results need to be confirmed 
with the use of Drp1 conditional knockout mice or Drp1 
dominant-negative adenoviruses. Third, our study mainly 
investigated the effects of Mdivi-1 in vivo. The complex 
underlying mechanisms mediating the protective effects 
need to be further explored in vitro.
Conclusions
The present study demonstrated a critical role of Drp1 in 
regulating mitochondrial fission and myocardial injury 
in diabetic mice undergoing MI/R. Pharmacological 
inhibition of Drp1 prevents mitochondrial fission and 
reduces MI/R injury in diabetic mice. Our findings sug-
gest that inhibition of Drp1 may be a potential novel 
therapeutic target for diabetic patients with ischemic 
heart disease.
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